Exercise Period for Warrants TO6 in Dicot Pharma Begins Today

Each warrant of series TO6 entitles the holder to subscribe for two new shares during the period March 17-31, 2025, at the subscription price of SEK 0.38 per warrant, equivalent to SEK 0.19 per share. If all warrants are exercised, Dicot Pharma will receive approximately SEK 45.7 million before costs.

To prevent the warrants from expiring worthless, the holder must actively subscribe for shares no later than March 31, 2025, or alternatively sell the warrants. The last day for selling and buying warrants (ticker "DICOT TO 6") on Nasdaq First North is March 27, 2025.

How to Exercise Warrants TO 6

Holders of nominee-registered warrants (held in a custody account, e.g., Avanza, Nordnet, or bank) make subscription and payment in accordance with the instructions from each respective custodian. Note that some custodians may close their application process earlier than March 31, 2025. For further information, please contact your custodian.

Holders of directly registered warrants (held in a VP account) will receive a pre-printed subscription form. For further information, see www.dicotpharma.com or www.aqurat.se.

More information on TO 6

A leaflet with information on how to subscribe, use of proceeds, etc. will be sent to both Dicot Pharma's option holders and shareholders registered in Sweden and should reach the recipients at latest March 20. The leaflet is also available at www.dicotpharma.com/en/investor-relations/reports-and-issues/to-6-warrants/.

Dicot Pharma will arrange a digital Q&A session on Thursday, March 20 at 12.30, which will also be available afterwards. The invitation is available at

https://www.dicotpharma.com/en/investor-relations/financial-calendar-and-events/.

Outcome
The outcome of the warrant exercise will be announced through a press release around April 2, 2025. Shares that have been subscribed for and paid will be registered in the subscriber's securities account as interim shares (IA) until the registration of the issuance has been completed with the Swedish Companies Registration Office, upon which the interim shares will automatically be converted into shares in Dicot Pharma AB.

For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: [email protected]

About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. 

Dicot Pharma is listed on Nasdaq First North and has approximately 9,100 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.